Company Encyclopedia
View More
name
SciSparc
SPRC.US
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form.
4.513 T
SPRC.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking0/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-1375.72%E
    • Profit Margin-4294.64%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-14.44%E
    • Net Profit YoY-837.30%E
    • Total Assets YoY0.00%C
    • Net Assets YoY-100.00%E
  • Cash ScoreD
    • Cash Flow Margin-2.33%D
    • OCF YoY-14.44%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio0.00%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Neurothera Labs to Acquire 55% Stake in Quantum Bio Data Company

    Neurothera Labs Inc., a subsidiary of SciSparc Ltd., plans to acquire a 55% stake in a quantum computing bio data analysis company. The deal involves issuing common shares equal to 40% of Neurothera's post-transaction share capital. The acquisition aims to enhance bio data analysis using quantum computing, subject to due diligence and agreement finalization.

    Reuters·
    US
    SPRC
    -1.69%
    Reuters·
    US
    SPRC
    -1.69%

    Scisparc Plans On Entering The Multi-Billion-Dollar Gerd Device Market With Acquisition Of An Approved IP Portfolio

    Scisparc Ltd :SCISPARC PLANS ON ENTERING THE MULTI-BILLION-DOLLAR GERD DEVICE MARKET WITH ACQUISITION OF AN APPROVED IP PORTFOLIOSCISPARC LTD - TO ISSUE 19.99% SHARE CAPITAL TO XYLO

    Reuters·
    US
    SPRC
    -1.69%
    Reuters·
    US
    SPRC
    -1.69%

    SciSparc Acquires MUSE System IP Portfolio from Xylo Technologies

    SciSparc Ltd. has signed a binding term sheet to acquire the MUSE™ system IP portfolio from Xylo Technologies Ltd. This includes patents, trademarks, and know-how for a device treating GERD. SciSparc will issue shares to Xylo, representing 19.99% of its share capital, with plans to expand into North America, Europe, and Latin America.

    Reuters·
    US
    SPRC
    -1.69%
    Reuters·
    US
    SPRC
    -1.69%

    Morning Trend | SciSparc consolidates and builds momentum, direction choice is coming?

    SciSparc (SPRC.US) has been in a "still water with slight ripples" state these days, but some in the community are closely watching for a turning point. On November 28th, it continued to fluctuate within the narrow range of $0.55 to $0.65, with trading volume so low that one might suspect "the main players have gone on vacation." There are no significant news in the sector, and the company has not made any substantial progress, leading short-term traders to focus entirely on technical charts—short moving averages are tangled like a chicken feather blanket on the half-minute K chart, with pressure and support balanced to the extreme. The atmosphere of "a sharp rise with a sudden surge in volume, or a sharp drop breaking the floor" is already quite evident. In this pattern of consolidation, community funds are exceptionally sensitive, and any unusual movements often trigger immediate feedback. Sudden announcements, unusual order sweeps, or partnership releases—any signal could spark a chain reaction of buying or selling. Because of this, many professional day traders are preparing to place breakout orders in advance, and the range-bound fluctuations have already compressed to a critical point. The conclusion is clear: once it breaks through $0.65 with volume, it will be a dilemma of rushing to exit or chasing the peak; if the main players drop it out of the range, stop-loss must be executed without hesitation. Short-term strategies can include buying on dips for rebounds or strong follow-ups on breakouts, but one must be quick and agile, closely observing the interplay of news, intraday movements, and community sentiment

    Technical Forecast·
    US
    SPRC
    -1.69%
    Technical Forecast·
    US
    SPRC
    -1.69%

    Morning Trend | SciSparc explores the bottom against the trend, is a stabilization counterattack signal coming?

    SciSparc (SPRC.US) showed a counter-trend bottom-fishing action during intraday trading yesterday after a continuous decline, leading to various discussions in community forums about the possibility of forming a rebound bottom. A closer look at the order book reveals that large funds have not significantly fled, and some main funds have even quietly increased their positions at lower levels. Once short-term speculative expectations resonate, it could easily trigger a wave of rapid buying. Currently, technical support signals are gradually emerging, with the lower shadows of the K-line noticeably elongated, historical trading volumes densely clustered, and local support strength increasing. The key is whether it can maintain above $1.10 today; if it can effectively hold, coupled with a slight increase in trading volume, it will confirm the start of this round of oversold rebound. If there is a sudden surge in volume during trading, it indicates that long-term funds are returning or there are new hot topics, making the rebound potential significant. On the negative side, sector sentiment remains divided, with some conservative funds on the sidelines and considerable disagreement within the trading community. During this weak rebound phase, stop-loss measures need to be strictly established, with the 1.02-1.05 range serving as a defense line; if breached, timely stop-loss measures should be taken. The overall news sentiment is neutral, but if there are innovative drug data or external merger and acquisition news, SPRC is likely to strengthen rapidly. Short-term advice is to closely monitor low-buy opportunities, and once signals of main funds increasing positions appear, act promptly without being overly attached to high-level profits. Capturing sudden changes in short-term sentiment is key to seizing the rebound gains of SPRC

    Technical Forecast·
    US
    SPRC
    -1.69%
    Technical Forecast·
    US
    SPRC
    -1.69%
    © 2025 Longbridge｜Disclaimer